Research record
Lifileucel tumor-infiltrating lymphocyte therapy
A T-cell therapy option to ask about after prior systemic therapy in the FDA-labeled context. It is not a simple infusion appointment and should be discussed at experienced centers.
What this is
A T-cell therapy option to ask about after prior systemic therapy in the FDA-labeled context. It is not a simple infusion appointment and should be discussed at experienced centers.
Why it may come up
- adult melanoma that cannot be removed by surgery or has spread
- after PD-1 blocking antibody
- if BRAF V600 positive, after BRAF inhibitor with or without MEK inhibitor
What not to assume
- Do not claim broad global availability.
- Do not simplify cell therapy into ordinary immunotherapy.
At a glance
Lifileucel tumor-infiltrating lymphocyte therapy
- Type
- Cell therapy
- Mutation result
- any, BRAF V600 context affects prior-therapy requirement
- Where
- US
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- FDA accelerated approval is based on response-rate evidence, with confirmatory obligations typical of accelerated approval.
- This should eventually become a dedicated treatment page because families often do not know TIL exists.
What is unclear
- Do not claim broad global availability.
- Do not simplify cell therapy into ordinary immunotherapy.
Questions to ask
- Is a TIL therapy center appropriate to consult?
- Would prior treatments or current disease location affect feasibility?
- How long would manufacturing and treatment logistics take?
Timeline
- approval2024: FDA accelerated approval
FDA accelerated approval for the source-cited unresectable/metastatic melanoma context after prior therapy.